ArticleBriefings in bioinformatics2025
Designing high-affinity 3D drug molecules via geometric spatial perception diffusion model.
Article in Briefings in bioinformatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Article
- Artificial intelligence-driven drug discovery: a deep learning paradigm shift in pharmaceutical research and development.Frontiers in pharmacology · 2026Review
- Artificial intelligence in drug discovery from advanced molecular representation to pipeline applications.Frontiers in bioinformatics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Designing high-affinity molecules for certain proteins is a fundamental and challenging problem for drug discovery, particularly when considering atomic interactions between molecules and proteins in 3D space. Current 3D molecular design methods are limited because they do not adequately capture the ligand molecular position information in Euclidean space. We proposed a diffusion model based on SE(3)-equivariant graph neural networks to enhance generated molecular binding affinity to protein targets using the long-range and distance-aware attention head mix. We also presented a molecular geometry feature enhancement strategy, further strengthening the perception of the spatial size of ligand molecules. Results show that, on the CrossDocked2020 dataset, our model outperforms the existing state-of-the-art models across various affinity-related metrics, including the Vina Score, and preserves essential drug-like properties. Our model excels in designing ligand molecules with macrocyclic structures. Additionally, it offers a moderate level of interpretability, aiding in understanding the binding interactions between 3D drug molecules and protein pockets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.